health ๐ฌ New ASCO 2026 guidelines change NSCLC treatment
The ASCO Living Guideline Version 2026.3.3 now emphasizes molecular profiling over just histology for Stage IV NSCLC. Clinicians must now use broad multigene profiling before starting systemic therapy, even if PD-L1 is high. For EGFR mutations, ASCO recommends intensifying frontline therapy with combination options like osimertinib plus platinum-pemetrexed. Furthermore, EGFR exon 20 insertions finally have a true targeted frontline choice with sunvozertinib or platinum-doublet chemotherapy plus amivantamab. These updates shift precision oncology into a more complex, risk-adapted phase. ๐ฌ